BioSpace News Archive

Adaptiiv, an innovative medical technology company announced today the United States Military will use 3D Bolus Software, Adaptiiv’s advanced software, in treating American veterans with cancer at Walter Reed National Military Medical Center (WRNMMC). Dubbed “The Nation’s Medical Center,” WRNMMC is the United States’ largest and most renowned joint military medical center that provides services in over 100 clinics and specialties.

Fabric Genomics a global leader in clinical interpretation of genomic data, and Genomenon®, the leading genomic data search company, announced today that they have entered into a partnership with the goal of further strengthening clinical genomic interpretation and variant classification.

Chanta Nelson from Powder Springs, Georgia, recently traveled to Tampa, Florida, to deliver the online student graduate address at the Ultimate Medical Academy (UMA) Fall Commencement ceremony.

Palmetto GBA issues final local coverage determination effective December 3, 2018

Partners have access to new platform tools that make it easier to build DNA powered products that leverage 100X more data from Helix’s CLIA-CAP accredited next-generation sequencing lab.

The Robert Wood Johnson Foundation has awarded $450,000 to the Rutgers Institute for Corporate Social Innovation (RICSI) to further its mission to prepare the next generation of business leaders by integrating social innovation, sustainability and shared value creation into Rutgers Business School’s curriculum.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it received notice from The Nasdaq Stock Market LLC “NASDAQ” indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5450(a)

Innovent Biologics, Inc. announces that the first patient has been dosed in a phase I clinical trial of anti-CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen-4) monoclonal antibody (IBI310) for patients with advanced solid tumors. IBI310 is a fully human monoclonal antibody that blocks CTLA-4.

COMPANY ALSO RECEIVES PRESTIGIOUS AWARD FOR ITS EFFORTS TO TACKLE THE OPIOID EPIDEMIC

Congress and the state of Pennsylvania approve language aimed at increasing access among underserved communities